This is a two part study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MK-1972 in participants with HIV-1 infections. In Part 1, participants will be randomized to receive MK-1972 (at one of 5 different dose levels given once or twice per day) or placebo. Part II will begin after the results of Part I are known; participants will be randomized to receive MK-1972 (only one dose level, twice per day) or placebo.

The area under the curve from 0-24 hours (AUC[0-24]) for plasma concentration of MK-1972 in participants with HIV-1 infection versus historical data from healthy young male subjects [ Time Frame: Day 10 ] [ Designated as safety issue: No ]

MK-1972 will be supplied as 25 and 100 mg capsules, and will be given orally, at a dose dependent on the treatment arm; participants will take ten capsules (active drug and/or placebo) twice per day for 10 days

Drug: Placebo to MK-1972

Placebo will be supplied as matching 25 and 100 mg capsules, and will be given orally, at a dose dependent on the treatment arm; participants will take ten capsules (active drug and/or placebo) twice per day for 10 days

Experimental: MK-1972 200 mg once daily

Drug: MK-1972

MK-1972 will be supplied as 25 and 100 mg capsules, and will be given orally, at a dose dependent on the treatment arm; participants will take ten capsules (active drug and/or placebo) twice per day for 10 days

Drug: Placebo to MK-1972

Placebo will be supplied as matching 25 and 100 mg capsules, and will be given orally, at a dose dependent on the treatment arm; participants will take ten capsules (active drug and/or placebo) twice per day for 10 days

Experimental: MK-1972 800 mg once daily

Drug: MK-1972

MK-1972 will be supplied as 25 and 100 mg capsules, and will be given orally, at a dose dependent on the treatment arm; participants will take ten capsules (active drug and/or placebo) twice per day for 10 days

Drug: Placebo to MK-1972

Placebo will be supplied as matching 25 and 100 mg capsules, and will be given orally, at a dose dependent on the treatment arm; participants will take ten capsules (active drug and/or placebo) twice per day for 10 days

Experimental: MK-1972 25 mg twice daily

Drug: MK-1972

MK-1972 will be supplied as 25 and 100 mg capsules, and will be given orally, at a dose dependent on the treatment arm; participants will take ten capsules (active drug and/or placebo) twice per day for 10 days

Drug: Placebo to MK-1972

Placebo will be supplied as matching 25 and 100 mg capsules, and will be given orally, at a dose dependent on the treatment arm; participants will take ten capsules (active drug and/or placebo) twice per day for 10 days

Experimental: MK-1972 100 mg twice daily

Drug: MK-1972

MK-1972 will be supplied as 25 and 100 mg capsules, and will be given orally, at a dose dependent on the treatment arm; participants will take ten capsules (active drug and/or placebo) twice per day for 10 days

Drug: Placebo to MK-1972

Placebo will be supplied as matching 25 and 100 mg capsules, and will be given orally, at a dose dependent on the treatment arm; participants will take ten capsules (active drug and/or placebo) twice per day for 10 days

Placebo Comparator: Placebo twice daily (Part I)

Drug: Placebo to MK-1972

Placebo will be supplied as matching 25 and 100 mg capsules, and will be given orally, at a dose dependent on the treatment arm; participants will take ten capsules (active drug and/or placebo) twice per day for 10 days

Experimental: MK-1972 800 mg twice daily

Drug: MK-1972

MK-1972 will be supplied as 25 and 100 mg capsules, and will be given orally, at a dose dependent on the treatment arm; participants will take ten capsules (active drug and/or placebo) twice per day for 10 days

Drug: Placebo to MK-1972

Placebo will be supplied as matching 25 and 100 mg capsules, and will be given orally, at a dose dependent on the treatment arm; participants will take ten capsules (active drug and/or placebo) twice per day for 10 days

Placebo Comparator: Placebo twice daily (Part II)

Drug: Placebo to MK-1972

Placebo will be supplied as matching 25 and 100 mg capsules, and will be given orally, at a dose dependent on the treatment arm; participants will take ten capsules (active drug and/or placebo) twice per day for 10 days

Eligibility

Ages Eligible for Study:

18 Years to 55 Years

Genders Eligible for Study:

Male

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria

Stable baseline health.

Appropriate use of contraception; condom protection with pregnant partners.

Documented HIV-1 positive

Anti-retroviral therapy (ART)-naïve, defined as having never received any antiretroviral agent or ≤30 consecutive days of an investigational antiretroviral agent, excluding an integrase inhibitor, or ≤60 consecutive days of combination ART excluding an integrase inhibitor.

No investigational agent or licensed ART within 30 days of study drug administration.

Use of any immune therapy agents or immunosuppressive therapy within 1 month prior to treatment in this study.

Requirement for chronic daily prescription medications.

Current (active) diagnosis of acute hepatitis due to any cause.

History of chronic Hepatitis C unless there has been documented cure and/or patient with a positive serologic test for Hepatitis C virus (HCV) has a negative HCV viral load.

Positive Hepatitis B surface antigen.

Refusal to stop using any medication, including prescription and non-prescription drugs or herbal remedies (such as St. John's Wort [Hypericum perforatum]) beginning approximately 2 weeks (or 5 half-lives) prior to administration of the initial dose of study drug, throughout the study (including washout intervals), until the post-study visit.

Consumption of excessive amounts, defined as greater than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, or other caffeinated beverages per day.

Smoker of more than 10 cigarettes/day unwilling to restrict smoking to ≤10 cigarettes per day.

Major surgery, donation or loss of 1 unit of blood (approximately 500 mL) or participation in another investigational study within 4 weeks prior to screening.

History of significant multiple and/or severe allergies (including latex allergy), or an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food.

Current regular user of any illicit drugs or has a history of drug (including alcohol) abuse within approximately 1 year. Patients with a positive cannabis test with no evidence of drug-dependency may be enrolled at the discretion of the investigator.

History of hepatic or gallbladder disease or history of clinically significant abnormalities in liver function tests, or history of Gilbert's Syndrome, or history of elevated unconjugated bilirubin.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.